The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

NCT ID: NCT00950677

Last Updated: 2017-04-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-07-31
• Study Completion Date: 2011-05-31

Brief Summary

The purpose of this study is to see if giving study drugs before a meal may lower blood sugars after the meal. An improvement in blood sugar control may prevent long-term problems of diabetes.

Detailed Description

A large study in people with type 2 diabetes (T2DM) showed that lowering blood sugars stopped or delayed the occurrence of health problems. As a result of the study, treatment should try to control blood sugars as near to normal as safely possible.

In people without diabetes, the "after meal" blood sugar level is very carefully controlled by several hormones. Insulin (the hormone that lowers blood sugar) and glucagon (hormone that raises blood sugar) play a key role in keeping this careful balance. Also, we now know of 2 new substances made by the body called amylin and GLP-1 that also help with this careful balance. Amylin is made in the pancreas. GLP-1 is made in the gut. We know that both amylin and GLP-1 are abnormal in people with diabetes.

There are two medicines that may help to control after meal blood sugars from going too high. The medicines are called Symlin (pramlintide) and Byetta (exenatide). Symlin works like amylin. Byetta works like GLP-1. Both medications are very similar in the ways that they work to control blood sugars.

Both medicines help to keep glucagon lower after a meal. They both also help the stomach to digest food more slowly so the blood sugar does not go up too fast after eating. They also help to control how much hunger a person may have before meals. This may help a person to eat less and possibly lose weight. Byetta also seems to help islet cells (cells that make insulin) make more insulin.

Byetta and Symlin are FDA approved for use in adults with T2DM. We want to study these drugs in children with T2DM.

Conditions

Type 2 Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

exenatide

exenatide one dose

Group Type: ACTIVE_COMPARATOR

Byetta (exenatide)

Intervention Type: DRUG

exenatide 5 mcg subcutaneously

pramlintide

pramlintide one dose

Group Type: ACTIVE_COMPARATOR

Symlin (pramlintide)

Intervention Type: DRUG

pramlintide 60 mcg subcutaneously

Interventions

Byetta (exenatide)

exenatide 5 mcg subcutaneously

Intervention Type: DRUG

Symlin (pramlintide)

pramlintide 60 mcg subcutaneously

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Children with Type 2 Diabetes,
• Between the ages of 12-21 years,
• Tanner stage 4-5 for pubertal development,
• Menstruating females must have a negative urine pregnancy test for inclusion,
• Must have T2DM for at least 6 months,
• History of negative anti-glutamic acid decarboxylase (GAD) -65 and anti-islet cell antibodies,
• HbA1c < 8.5% and on a stable dose of an oral hypoglycemic agent (with or without insulin) over the last 2 months, or well controlled on diet.

Exclusion Criteria

• A history of a chronic disease other than diabetes (leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis, dyslipidemia, cholelithiasis etc),
• BMI> 40 kg/m2,
• Weight of < 60 kg,
• Female with menstrual irregularities,
• Allergy to local anesthetics (ELAMAX Cream, Ethyl Chloride),
• Evidence or history of chemical abuse,
• Anemia (age specific normal range for hemoglobin will be used),
• Elevated liver enzymes (defined as more than 3 times the upper limit of the normal range for age),
• Elevated BUN or creatinine (defined as more than 3 times the upper limit of the normal range for age),
• Use of medications that may increase the blood sugars and admission to the hospital for diabetes related problems over the last 6 months.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role: collaborator

Baylor College of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Luisa M. Rodriguez

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

LUISA M RODRIGUEZ, MD

Role: PRINCIPAL_INVESTIGATOR

Baylor College of Medicine

Locations

Baylor College of Medicine

Houston, Texas, United States

Countries

United States

Other Identifiers

K23DK075931

Identifier Type: NIH

Identifier Source: secondary_id

View Link

H-22439

Identifier Type: -

Identifier Source: org_study_id